New Japanese Patent paOvarian Cancer Vaccine

rakanyorwa mupepeti

Anixa Biosciences, Inc., kambani yebiotechnology yakatarisana nekurapa nekudzivirira gomarara nezvirwere zvinotapukira, nhasi yazivisa kuti Hofisi yePatent yeJapan yapa Chisungo chekupa patent kuCleveland Clinic yakanzi, "Ovarian Cancer Vaccines." Tekinoroji yakagadzirwa naDr. Vincent K. Tuohy, Suparna Mazumder naJustin M. Johnson paCleveland Clinic. Anixa ndiye ane rezinesi repasi rose retekinoroji yekudzivirira. Patents yetekinoroji yakapihwa muUS neEurope muna 2021.  

Print Friendly, PDF & Email

"Tinofara kuzivisa iyi yekuwedzera kuchengetedzwa kwepfuma yekudzivirira kwechirwere chegomarara reOvarian chaAnixa, chakagadzirwa kuCleveland Clinic uye chiri kudzidzwa kuNCI. Iyi tekinoroji yakasarudzika ine mukana wekuva mushonga wekutanga kudzivirira kenza yeovarian, iyo inoramba iri imwe yeanonyanya kukuvadza uye yakaoma-kurapa kenza, "akadaro Dr. Amit Kumar, CEO, Mutungamiriri uye Sachigaro weAnixa Biosciences. “Kana ikabudirira, jekiseni iri rinogona kudzivirira gomarara remuchibereko kuti rirege kuitika uye kudzivirira varwere kubva mukurapwa chemotherapy nekuvhiyiwa kwakanyanya, uye zvinogona kuponesa hupenyu. Tinotarisira kuenderera mberi nebasa redu rekutanga netarisiro yekuti jekiseni iri richawedzera kune arsenal inodiwa kunangana negomarara iri rakaoma uye nekupedzisira mutsauko kuvarwere vazhinji. "

Mushonga wegomarara reovarian unonangana neiyo extracellular domain ye anti-Müllerian hormone receptor 2 (AMHR2-ED), iyo inoratidzwa mumaovari asi inonyangarika apo mukadzi anosvika nekufambira mberi kuburikidza nekuenda kumwedzi. Zvecherechedzo, ruzhinji rwegomarara reovarian rinowanikwa mushure mekuenda kumwedzi, uye AMHR2-ED inoratidzwa zvakare muhuwandu hwekenza yemaovari. Nekugamuchira mushonga wakaita seAnixa's unonangana neAMHR2-ED mushure mekusvika kumwedzi, gomarara reovarian, iro ragara riri rimwe rechirwere chegomarara revakadzi, rinogona kudzivirirwa kubva pakuitika.

Preclinical basa rekusimudzira vaccine ririkuenderera mberi kuburikidza nePREVENT Chirongwa kuNational Cancer Institute (NCI), iyo inotsigira preclinical innovative kupindira uye biomarker yekudzivirira gomarara uye kubata. Preclinical data yakaburitswa muCancer Prevention Research muna 2017 inotsigira kuenderera mberi kuzvidzidzo zvekiriniki.

Print Friendly, PDF & Email

Nezvomunyori

mupepeti

Mupepeti mukuru we eTurboNew ndiLinda Hohnholz. Iye anogara muTN HQ muHonolulu, Hawaii.

Leave a Comment